New study finds some US hospitals mark up medicine prices at least 700%

6 September 2018

A new analysis from The Moran Company found nearly one in five hospitals in the USA marks up medicine prices 700% or more.

With this 700% markup, a $150 medicine purchased by a hospital could cost patients up to $1,050, according to a posting on the Pharmaceutical Research and Manufacturers of America website by Holly Campbell, a deputy vice president of public affairs at PhRMA.

The study, which was commissioned by PhRMA and looked at total costs and charges for all medicines from 3,792 hospitals using Centers for Medicare and Medicaid Services (CMS) data, also found:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK